Leukemia Research
Volume 22, Issue 11 , Pages 1049-1056, November 1998

Characterization of cytotoxicity induced by sphingolipids in multidrug-resistant leukemia cells

Department of Tumor Biology, Box 108, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA

Received 4 February 1998; accepted 23 May 1998.

Abstract 

Certain sphingolipids (SLs) exert fundamental roles in differentiative, growth-inhibitory and apoptotic pathways induced by a number of agents in leukemia cells. Multidrug-resistance (MDR) is a major cause of therapeutic failure in leukemia. SLs are among the diverse substrates for the MDR p-170 glycoprotein drug-efflux pump. We tested the hypothesis that expression of MDR would thereby block the cytotoxicity induced by the SLs sphingosine, sphinganine and N-hexanoyl-sphingosine. An MDR-expressing subline of murine P388 leukemia cells demonstrated an ED50 value ≥2log10 higher than the parental line in response to doxorubicin. In contrast, the ED50 values for each of the SLs were only approximately 1.5 to two-fold higher in the MDR line than in the parental; induction of DNA damage by SLs was comparable or actually greater in MDR compared to parental cells. Therefore, expression of MDR does not significantly affect the cytotoxic function of these SLs, nor do these SLs likely contribute to MDR.

Keywords:  Chemoresistance, Cytotoxicity/Apoptosis, Sphingosine, Ceramide

Abbreviations:  C6-ceramide or C6-Cer, N-hexanoyl-d-sphingosine, Dox, doxorubicin, ED50, effective dose inducing 50% effect, MDR, multidrug-resistance, P-gp, P-glycoprotein, Sa, sphinganine (dihydrosphingosine), Sls, sphingolipids, SM, sphingomyelin, SMase, sphingomyelinase, So, d-sphingosine

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0145-2126(98)00107-6

Leukemia Research
Volume 22, Issue 11 , Pages 1049-1056, November 1998